Professor Gerhardt investigates the formation of blood vessels (angiogenesis) in organism and disease development and is seeking ways to stop pathological vessel growth. One of its triggers is the vascular endothelial growth factor (VEGF). For many years it has been known that tumors ensure their supply of oxygen and nutrients by secreting VEGF into nearby tissue. VEGF docks onto the receptors of blood vessels, inducing new blood vessels to grow towards the tumor. “Without a blood supply, a tumor can only grow to the size of a grain of salt,” Professor Gerhardt said, explaining the significance of this process.
How blood vessels grow towards tumors
More than ten years ago Professor Gerhardt discovered how blood vessels grow towards the cells that secrete the growth factor. Once the factor docks to the receptor on the surface, a cell sprouts from this blood vessel, positioning itself at the tip of the new blood vessel that is to be formed. This tip cell attracts additional cells (stalk cells) from the original blood vessel. “In our research we discovered that the individual cells that form new vascular sprouts are constantly moving and changing places. There is even direct competition between the cells. Each cell apparently tries to take the lead position just like cyclists participating in the Belgian Omloop race,” said Professor Gerhardt explaining this process. Working together in this way, the cells build up the new blood vessel piece by piece, which then connects with other blood vessels to form an entire vascular network.
In 2011 Professor Gerhardt received the Judah Folkman Award of the North American Vascular Biology Organization (NAVBO) for the discovery of these fundamental principles of blood vessel sprouting. The award is named after the Harvard professor Judah Folkman, who was the first researcher to discover that tumors themselves ensure their oxygen and nutrient supply by signaling blood vessels to grow towards and into them.
Collaboration with clinicians
In Berlin Professor Gerhardt intends to continue his research and to collaborate in particular with clinical cooperation groups. The objective is to better understand angiogenesis in diseases, especially in tumors, and on this basis to develop new concepts for therapy.
Holger Gerhardt was born in Mannheim on May 14, 1969 and studied biology at Technische Universität Darmstadt and the University of Tübingen. In 2000 he received a doctorate from the University of Tübingen with a dissertation on the blood-brain barrier. Then he went for four years as a postdoctoral fellow to Professor Christer Betsholtz at the Institute of Medical Biochemistry of the University of Gothenburg, Sweden. In 2004 he became a junior research group leader at the London Research Institute and in 2009 became a research group leader there. During this time, he was also head of a research group at Vesalius Research Center at the Catholic University of Leuven.
Besides the Judah Folkman Award, Holger Gerhardt has also received further awards, including the Dissertation Award of the Reinhold and Maria Teufel Foundation, Tuttlingen (2001), the EMBO Young Investigator Award (2007), the Lister Research Prize, England (2008), the Walther Flemming Medal of the German Society for Cell Biology (2009) and the Hooke Medal of the British Society for Cell Biology (2012).
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
in the Helmholtz Association
Phone: +49 (0) 30/ 9406 - 3896
Charité – Universitätsmedizin Berlin
Phone: +49 (0) 30/ 450 570 - 400
German Centre for Cardiovascular Research (DZHK) e. V.
Phone: +49 (0) 30/ 4593 - 7102
E-Mail: ; http://dzhk.de/1/
Berliner Institut für Gesundheitsforschung (BIG)/Berlin Institute of Health (BIH)
Phone: +49 (0) 30/ 9406 - 2068